1-Butyl-3-(1-naphthoyl)indole
Common Name: |
1-Butyl-3-(1-naphthoyl)indole |
IUPAC Name: |
(1-butylindol-3-yl)-naphthalen-1-ylmethanone |
Molecular Formula: |
C23H21NO |
SMILES: |
CCCCN1C=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=CC=CC=C43 |
Inchi: |
1S/C23H21NO/c1-2-3-15-24-16-21(19-12-6-7-14-22(19)24)23(25)20-13-8-10-17-9-4-5-11-18(17)20/h4-14,16H,2-3,15H2,1H3 |
Inchi Key: |
VCHHHSMPMLNVGS-UHFFFAOYSA-N |
Cas No: |
208987-48-8 |
Name |
Value |
Lipinski Violations |
0 |
Ghose Violations |
1 |
Veber Violations |
0 |
Egan Violations |
0 |
Muegge Violations |
1 |
Name |
Value |
Molecular Weight (g/mol) |
327.42 |
Mass (g/mol) |
327.162 |
Molar Refractivity |
105.00 |
Net Charge |
|
HBD |
|
HBA |
1 |
Rt Bonds |
5 |
Rings |
4 |
TPSA |
22.00 |
Hetero Atoms |
2 |
Heavy Atoms |
25 |
Aromatic Heavy Atoms |
19 |
Melting Point (°C) |
|
Boiling Point (°C@760.00mm Hg) |
|
Vapor Pressure (mmHg@25.00 °C) |
9.86X10-10 |
Vapor Density (Air =1) |
|
Fraction Csp3 |
0.17 |
LogP |
5.826 |
iLOGP |
3.55 |
XLOGP3 |
5.78 |
WLOGP |
5.83 |
MLOGP |
3.98 |
ESOL Log S |
-5.74 |
ESOL Solubility (mg/ml) |
0.001 |
ESOL Solubility (mol/l) |
0 |
ESOL Class: esol_class |
Moderately soluble |
Ali Log S |
-6.01 |
Ali Solubility (mg/ml) |
0 |
Ali Solubility (mol/l) |
0 |
Ali Class |
Poorly soluble |
Silicos-IT LogSw |
-8.18 |
Silicos-IT Solubility (mg/ml) |
0 |
Silicos-IT Solubility (mol/l) |
0 |
Silicos-IT Class |
Poorly soluble |
Name |
Value |
GI Absorption |
High |
BBB Permeable |
0 |
PgP Substrate |
1 |
Log Kp (cm/s) |
-4.19 |
Bioavailability Score |
0.55 |
Caco2 |
1 |
Human Intestinal Absorption |
1 |
Plasm Protein Binding |
0.918 |
CYP1A2 Inhibitor |
1 |
CYP2C19 Inhibitor |
1 |
CYP2C9 Inhibitor |
1 |
CYP2D6 inhibitor |
1 |
CYP3A4 inhibitor |
1 |
Ames mutagenesis |
0 |
Acute Oral Toxicity |
2.101 |
Carcinogenicity (Binary) |
0 |
Carcinogenicity (Trinary) |
Non-required |
Eye Irritation |
0 |
Hepatotoxicity |
1 |
Androgen Receptor Binding |
1 |
Aromatase Binding |
1 |
Estrogen Receptor Binding |
1 |
Glucocorticoid Receptor Binding |
1 |
Thyroid Receptor Binding |
1 |
BRCP inhibitor |
0 |
BSEP inhibitor |
1 |
OATP1B1 inhibitor |
1 |
OATP1B3 inhibitor |
1 |
OATP2B1 inhibitor |
0 |
OCT1 inhibitor |
1 |
OCT2 inhibitor |
1 |